PDE6A-associated RP, a rare form of inherited retinal disease (IRD), is characterized by nyctalopia, visual field defects, and significant loss of visual acuity (VA). The disease primarily affects the ...

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential. One might ask why topical eye drop medications remain the mainstay of glaucoma therapy in the US and ...

New AAV therapy for retinitis pigmentosa completes Phase I/II dosing, aiming to protect cones and slow vision loss; first ...

Oluwatosin U. Smith, MD, highlights how the foundation provides education, research, and access-to-care for patients and ...

Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before ...

China’s National Medical Products Administration (NMPA) has granted regulatory approval for 2 next-generation ophthalmic ...

Collapsing physicians into an undifferentiated “provider” category can obscure differences in expertise and accountability, complicating informed patient navigation of multidisciplinary teams.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell ...

Ocular surface disease (OSD) is a prevalent yet frequently underrecognized challenge in the management of glaucoma. A ...

Edinburgh Biosciences has reported encouraging early outcomes from a structured long-term safety and performance follow-up ...

The 2025 program built on its evolving reputation as a multispecialty educational forum that successfully integrates ophthalmology and optometry, premium CME content, and a family-friendly format to ...

Enzeevum, a biosimilar to Eylea, is approved in Canada for multiple retinal conditions, expanding treatment options for ...